文献速递免疫规划传染病防控与疫情报告

Ad5载体新冠疫苗不增加HIV感染风险

Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection.
PubMed 文献 · Vaccine · 2026-03-04

基于一项在五国开展的双盲随机对照三期试验,纳入43,780名有基线HIV检测结果的受试者,分析Ad5-nCoV疫苗接种与HIV感染风险的关系。

要点

  • Ad5-nCoV接种后6个月内HIV新发率与安慰剂组相近,未增加短期感染风险。
  • 接种前HIV患病率在疫苗组与安慰剂组间无差异,分层分析结果一致。

核心结论

  • Ad5-nCoV未增加普通人群短期HIV感染风险,且不受既往Ad5中和抗体影响。

研究设计与样本

  • 2020年9月至2021年3月在阿根廷、智利、墨西哥、俄罗斯和巴基斯坦66个中心开展的双盲随机安慰剂对照三期试验,共纳入44,247名受试者,按1:1随机分配接种Ad5-nCoV或安慰剂。

临床怎么用

  • 为Ad5载体疫苗的安全性提供依据,可用于回应公众对Ad5载体疫苗可能增加HIV感染风险的担忧。

局限性

  • HIV新发分析仅基于接种后6个月数据,为短期风险评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a concern about the potential increased risk of acquiring HIV infection after vaccination with adenovirus type 5 (Ad5) vector-based vaccines. We aimed to investigate whether Ad5-nCoV increases the risk of HIV infection. METHODS: Between September 2020 and March 2021, a Phase 3 clinical trial was executed to evaluate the efficacy of Ad5-nCoV. This trial, employing a double-blind, randomized, and placebo-controlled design, enrolled 44,247 participants from 66 clinical sites spanning Argentina, Chile, Mexico, Russia, and Pakistan. Participants were allocated randomly in a 1:1 ratio to receive either Ad5-nCoV or a placebo, and their HIV-negative status was assessed by self-report and confirmed by HIV testing on a baseline blood sample at the end of the study. Consequently, individuals initially administered a placebo received one dose of Ad5-nCoV, while those initially given Ad5-nCoV finally received two doses, with an interval of approximately 6-10 months between administrations. The trial design and primary outcomes have been previously reported. This analysis involves a comprehensive assessment of the associations between pre-existing Ad5 neutralizing antibodies, HIV prevalence and incidence before and after vaccination while accounting for demographic variables. RESULTS: A total of 43,780 participants who had valid HIV baseline testing results were included in this study. Prior to vaccination, there was no discernible difference in HIV prevalence between the placebo group (0·39% of 21,877 participants) and the Ad5-nCoV group (0·38% of 21,893 participants). This similarity persisted when the data were stratified by country, gender, age, and race. Paired analyses assessing HIV incidence were conducted on participants who tested negative for HIV before vaccination, with data collected over a 6-month period post-vaccination. The results revealed notable similarity in HIV incidence across all groups: 0·29% for Group A (Ad5-nCoV group), 0·21% for Group B (Placebo group), 0·27% for group A + D (Ad5-nCoV group and 1 × Placebo+1 × Ad5-nCoV group), 0·1% for Group C (2 × Ad5-nCoV group), and 0·25% for Group A + C + D (participants who received at least one dose of Ad5-nCoV). Testing approximately 100 randomly chosen participants in each country revealed a similar distribution of pre-existing Ad5 neutralizing antibodies (Nab), with the ratio above a titer of 200 ranged from 65·42% to 67·71%. Notably, the heightened presence of pre-existing Ad5 Nab did not result in an increased risk of HIV infection. CONCLUSION: The Ad5-nCoV did not increase the short-term risk of HIV infection in this large and diverse sample of the general population, regardless of the presence of pre-existing Ad5 Nab providing valuable insights into the safety of Ad5 vector-based vaccines. CLINICALTRIALS: gov, NCT04526990.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ruiz-Palacios GM, Cahn PE, Halperin SA, et al. Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection. Vaccine. 2026. PMID: 41785679. doi:10.1016/j.vaccine.2026.128378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。